Antiviral Therapies Market Size To Reach USD 46.21 Billion, Globally, By 2026 | F. Hoffmann-La Roche Ltd., Gilead Sciences

According to the research report published by Allied Market Research, the global Antiviral Therapies market is expected to register a CAGR of 2.4% from 2019 to 2026. The research includes changing market dynamics, top impacting factors, key investment pockets, value chain, and competitive scenario. Through tabular and graphical representation, the report offers key insights on different aspects of the market such as current market size and estimations, region-wise analysis, and opportunities. Porter’s Five Forces analysis has been mentioned in the report to outline competitive intensity. The report is a helpful source of information to unlock potential from emerging countries and expand businesses to gain international presence.

Antiviral therapies make use of drugs that inhibit the development of the virus causing infection. These drugs do not kill the target pathogen directly. These therapies are mostly particular against viral infections and do not cause side effects in the host’s body. Anti-viral therapies are widely used in treating HIV, herpes, hepatitis, influenza and other viral infections such as chicken pox and papilloma.

Click Here To Access Free Sample Report @ https://www.alliedmarketresearch.com/purchase-enquiry/6643

The factors that drive the growth of the market include rise in prevalence of viral infections globally and presence of robust product pipeline with several pharmaceutical giants. Conversely, higher cost for treating these infections and shift in preference of the patients toward homeopathy and naturopathy are some of the key issues expected to hinder the antiviral therapies market growth. On the contrary, R&D for developing combination therapies to effectively eradicate the infections is anticipated to provide lucrative opportunities for the growth of the anti-viral therapies market during the forecast period.

The global antiviral therapies market is segmented on the basis of application, type, mechanism of action, and region. Based on type, the branded drugs segment contributed to the largest share in 2018, accounting for more than half of the total share, and is estimated to maintain its dominant position during the forecast period. However, the generic drugs segment is expected to register the highest CAGR of 2.5% from 2019 to 2026.

Based on mechanism of action, the nucleotide polymerase inhibitor segment accounted for the largest share in 2018, holding nearly two-fifths of the total share, and is expected to maintain the largest share throughout the forecast period. However, the reverse transcriptase inhibitors segment is estimated to portray the highest CAGR of 3.1% during the forecast period.

Based on region, North America contributed the highest share, accounting for more than one-third of the total market share in 2018, and will maintain its dominance throughout the forecast period. However, Asia-Pacific is expected to grow at the highest CAGR of 2.8% from 2019 to 2026.

Inquire Before Buying @ https://www.alliedmarketresearch.com/request-sample/6643

The Major Key Players Are:

• F.Hoffmann-LaRocheLtd.
• GileadSciences
• GlaxoSmithKline
• Bristol-Myers-Squibb
• AbbottLaboratories
• AstraZenecaplc
• AbbVieInc.
• AurobindoPharmaLimited
• Johnson&Johnson
• Merck&Co.,Inc.

The other Key players Are:

• Schering-PloughCorporation
• Cipla
• DrReddy’s.

Key Findings Of The Study:

• Nucleotide polymerase inhibitor segment occupied 38.44% share of the global anti-viral therapies market in 2018.
• By application, HIV segment is anticipated to grow with the highest CAGR throughout the forecast period.
• By type, the generic drugs segment accounted for 46.8% share of the market in 2018.
• Asia-Pacific is anticipated to grow at the 2.8% during the analysis period.

Access Full Report @ https://www.alliedmarketresearch.com/anti-viral-therapies-market-A06278

Contact:

David Correa
Portland, OR, United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

This release was published on openPR.